MTB
41
-3
V
42
-8
HCA
37
-11
FSLR
52
-3
KO
42
-4
MLM
29
-3
WFC
47
-8
T
33
-2
AMG
52
-2
FITB
36
-2
PG
32
-6
HPE
53
15
MSFT
39
-4
NWSA
58
-2
DTE
56
-7
NEM
53
-2
IBM
44
-4
ORLY
41
-3
AEE
58
-5
LMT
25
-4
MTB
41
-3
V
42
-8
HCA
37
-11
FSLR
52
-3
KO
42
-4
MLM
29
-3
WFC
47
-8
T
33
-2
AMG
52
-2
FITB
36
-2
PG
32
-6
HPE
53
15
MSFT
39
-4
NWSA
58
-2
DTE
56
-7
NEM
53
-2
IBM
44
-4
ORLY
41
-3
AEE
58
-5
LMT
25
-4
Financhill
Back

Intra-Cellular Therapies 10K Form

Sell
42

ITCI
Intra-Cellular Therapies

Last Price:
$94.86
Seasonality Move:
2.9%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ITCI News And Ratings

See the #1 stock for the next 7 days that we like better than ITCI

ITCI Financial Statistics

Sales & Book Value

Annual Sales: $462.2M
Cash Flow: $-27.2M
Price / Cash Flow: 0
Annual Sales: $10.80
Price / Book: 8.79

Profitability

EPS (TTM): -0.87000
Net Income (TTM): $-86.4M
Gross Margin: $428.4M
Return on Equity: -10.58%
Return on Assets: -8.93%

Intra-Cellular Therapies Earnings Forecast

Key Intra-Cellular Therapies Financial Ratios

  • The Gross Profit Margin over the past 10 years for ITCI is 92.70%.
  • The Selling, General & Administrative Expenses for ITCI have been equal to 88.68% of Gross Profit Margin.
  • The Research & Development expenses have been 38.98% of Revenue.
  • Per Share Earnings over the last 12 years have been positive in 6 years.

Intra-Cellular Therapies Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ITCI
CUSIP: 46116X
Website: intracellulartherapies.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 7.66
Quick Ratio: 6.94

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 27.39

ITCI Technical Analysis vs Fundamental Analysis

Sell
42
Intra-Cellular Therapies (ITCI) is a Sell

Is Intra-Cellular Therapies a Buy or a Sell?